1. Market Research
  2. > Glioma - Pipeline Review, H2 2013

Glioma - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 154 pages

Glioma - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Glioma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioma. Glioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Glioma.
- A review of the Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glioma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Glioma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glioma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Glioma - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Glioma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Glioma 9
Glioma Therapeutics under Development by Companies 11
Glioma Therapeutics under Investigation by Universities/Institutes 14
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Glioma Therapeutics - Products under Development by Companies 19
Glioma Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Glioma Therapeutics Development 22
Genzyme Corporation 22
Vical Incorporated 23
Amgen Inc. 24
Eli Lilly and Company 25
Nektar Therapeutics 26
Merck and Co., Inc. 27
Histogen, Inc. 28
Cell Therapeutics, Inc. 29
AntiCancer, Inc. 30
GW Pharmaceuticals plc 31
AEterna Zentaris Inc. 32
Novogen Limited 33
Telik, Inc. 34
Natco Pharma Limited 35
Domain Therapeutics 36
immatics biotechnologies GmbH 37
Crusade Laboratories Limited 38
Advantagene, Inc. 39
Hawthorn Pharmaceuticals, Inc. 40
Merrimack Pharmaceuticals, Inc. 41
Deciphera Pharmaceuticals, LLC 42
MSM Protein Technologies, Inc. 43
TVAX Biomedical, LLC 44
to-BBB technologies BV 45
Targepeutics, Inc. 46
Lipopharma 47
Kringle Pharma, Inc. 48
Galaxy Biotech, LLC 49
Almac Discovery Ltd. 50
Neumedicines Inc. 51
DEKK-TEC, Inc. 52
Glioma - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 60
HuL-2G7 - Drug Profile 60
fresolimumab - Drug Profile 62
paclitaxel poliglumex - Drug Profile 64
etirinotecan pegol - Drug Profile 68
IMA-950 - Drug Profile 71
GWP-42002 - Drug Profile 73
TLK-58747 - Drug Profile 74
irinotecan sucrosofate - Drug Profile 75
NK-4 Protein - Drug Profile 77
TRP-2 Vaccine - Drug Profile 78
Dendritic Cell Vaccine - Drug Profile 79
vorinostat - Drug Profile 80
GliAtak - Drug Profile 83
TVI-Brain-1 - Drug Profile 84
NRC-AN-019 - Drug Profile 86
Haw mAb-11 - Drug Profile 88
galunisertib - Drug Profile 89
ALM-301 - Drug Profile 91
Genetically Engineered Mesenchymal Stem Cells - Drug Profile 92
BACPT DP - Drug Profile 93
GWP-42003 - Drug Profile 94
AMG-595 - Drug Profile 96
Tumor Lysate Vaccine + [imiquimod] - Drug Profile 98
HSV-1716 - Drug Profile 99
Tumor Lysate Vaccine + Fc-OX40L - Drug Profile 100
GDOX - Drug Profile 101
Nampt Inhibitors - Drug Profile 102
KC-7F2 - Drug Profile 103
Triaryl NADPH Oxidase Inhibitor - Drug Profile 104
DNAzymes - Drug Profile 105
BK-1361 - Drug Profile 106
CS-6 Program - Drug Profile 107
Antibody Drug For Glioma - Drug Profile 108
NMHSS-1 - Drug Profile 109
DP-6865 - Drug Profile 110
Cell Therapy For Glioma - Drug Profile 111
MSM-608 - Drug Profile 112
TBio-01 - Drug Profile 113
mGluR3 NAM - Drug Profile 115
GLIAT Project - Drug Profile 116
Xaripin D - Drug Profile 117
Xaripin P - Drug Profile 118
Salmonella typhimurium A1-R - Drug Profile 119
Fenoterol Analogues - Drug Profile 120
Embryonic-Like Human Extracellular Matrix - Drug Profile 121
Glioma Therapeutics - Drug Profile Updates 122
Glioma Therapeutics - Discontinued Products 138
Glioma Therapeutics - Dormant Products 139
Glioma - Product Development Milestones 141
Featured News and Press Releases 141
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151



List of Tables

Number of Products Under Development for Glioma, H2 2013 12
Products under Development for Glioma - Comparative Analysis, H2 2013 13
Number of Products under Development by Companies, H2 2013 15
Number of Products under Development by Companies, H2 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2013 18
Comparative Analysis by Mid Clinical Stage Development, H2 2013 19
Comparative Analysis by Early Clinical Stage Development, H2 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 21
Products under Development by Companies, H2 2013 22
Products under Development by Companies, H2 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2013 24
Genzyme Corporation, H2 2013 25
Vical Incorporated, H2 2013 26
Amgen Inc., H2 2013 27
Eli Lilly and Company, H2 2013 28
Nektar Therapeutics, H2 2013 29
Merck and Co., Inc., H2 2013 30
Histogen, Inc., H2 2013 31
Cell Therapeutics, Inc., H2 2013 32
AntiCancer, Inc., H2 2013 33
GW Pharmaceuticals plc, H2 2013 34
AEterna Zentaris Inc., H2 2013 35
Novogen Limited, H2 2013 36
Telik, Inc., H2 2013 37
Natco Pharma Limited, H2 2013 38
Domain Therapeutics, H2 2013 39
immatics biotechnologies GmbH, H2 2013 40
Crusade Laboratories Limited, H2 2013 41
Advantagene, Inc., H2 2013 42
Hawthorn Pharmaceuticals, Inc., H2 2013 43
Merrimack Pharmaceuticals, Inc., H2 2013 44
Deciphera Pharmaceuticals, LLC, H2 2013 45
MSM Protein Technologies, Inc., H2 2013 46
TVAX Biomedical, LLC, H2 2013 47
to-BBB technologies BV, H2 2013 48
Targepeutics, Inc., H2 2013 49
Lipopharma, H2 2013 50
Kringle Pharma, Inc., H2 2013 51
Galaxy Biotech, LLC, H2 2013 52
Almac Discovery Ltd., H2 2013 53
Neumedicines Inc., H2 2013 54
DEKK-TEC, Inc., H2 2013 55
Assessment by Monotherapy Products, H2 2013 56
Assessment by Combination Products, H2 2013 57
Assessment by Stage and Route of Administration, H2 2013 59
Assessment by Stage and Molecule Type, H2 2013 62
Glioma Therapeutics - Drug Profile Updates 125
Glioma Therapeutics - Discontinued Products 141
Glioma Therapeutics - Dormant Products 142
Glioma Therapeutics - Dormant Products (Contd..1) 143



List of Figures

Number of Products under Development for Glioma, H2 2013 12
Products under Development for Glioma - Comparative Analysis, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 17
Mid Clinical Stage Products, H2 2013 19
Early Clinical Stage Products, H2 2013 20
Discovery and Pre-Clinical Stage Products, H2 2013 21
Assessment by Monotherapy Products, H2 2013 56
Assessment by Combination Products, H2 2013 57
Assessment by Route of Administration, H2 2013 58
Assessment by Stage and Route of Administration, H2 2013 59
Assessment by Molecule Type, H2 2013 60
Assessment by Stage and Molecule Type, H2 2013 61



Companies Mentioned

Genzyme Corporation
Vical Incorporated
Amgen Inc.
Eli Lilly and Company
Nektar Therapeutics
Merck and Co., Inc.
Histogen, Inc.
Cell Therapeutics, Inc.
AntiCancer, Inc.
GW Pharmaceuticals plc
AEterna Zentaris Inc.
Novogen Limited
Telik, Inc.
Natco Pharma Limited
Domain Therapeutics
immatics biotechnologies GmbH
Crusade Laboratories Limited
Advantagene, Inc.
Hawthorn Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
MSM Protein Technologies, Inc.
TVAX Biomedical, LLC
to-BBB technologies BV
Targepeutics, Inc.
Lipopharma
Kringle Pharma, Inc.
Galaxy Biotech, LLC
Almac Discovery Ltd.
Neumedicines Inc.
DEKK-TEC, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.